Valiant Organics Limited · NSE:VALIANTORG
Valiant Organics — Q2 FY24 Earnings Presentation
25 slides from Valiant Organics's earnings presentation, Nov 9, 2023
Slide 1: Cover letter to stock exchanges
November 09, 2023 To, To, Listing/Compliance Department Listing/Compliance Department BSE LTD National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, “Exchange Plaza”, Plot No. C/1, Mumbai- 400 001. G Block Bandra-Kurla Complex, Bandra (E), Mumbai- 400 051. SCRIP CODE - 540
Slide 2: Earnings Presentation | Q2/H1-FY24
Earnings Presentation | Q2/H1-FY24
Slide 3: Snapshot
SNAPSHOT One of the largest chlorophenol One of the leading manufacturer of derivatives manufacturer globally Benzene derivatives products One of the largest domestic PNA One of the few commercial players in manufacturer Ortho Anisidine and Para Anisidine Diversified client base across Amongst 1st f
Slide 4: Company Overview
Company Overview Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India. The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmac
Slide 5: Chemistries And Product Basket
Chemistries And Product Basket H1-FY24 Revenue Share Hydrogenation Ammonolysis 43% Key Products: Industries Served: Key Products: Industries Served: • Ortho Anisidine • Dyes • Para Nitro Aniline • Para Anisidine • Dyes • Pigments • Ortho Chloro Para Nitro Aniline • Pigments • IPPCA • Pharmaceutical
Slide 6: Manufacturing Footprint
Manufacturing Footprint CHLORINATION – SARIGAM HYDROGENATION & METHOXYLATION- • Capacity: 18,000 MTPA JHAGADIA UNIT 1 • Products: PCP, OCP, 2,4 DCP, 2,6 DCP, • Capacity: 27,000 MTPA 2,4,6 TCP • Products: ONA/OA, PNA/PA, IPPCA, CONVERSION PRODUCTS AMMONOLYSIS - VAPI HYDROGENATION – JHAGADIA UNIT 2 •
Slide 7: Key Strengths
Key Strengths Domain expertise and broad Plant locations are process understanding in a Wide supply chain strategically located near variety of chemistries. The provides the continuous ports to provide a executive team is made up of availability of adequate competitive advantage, first-generation te
Slide 8: Capex Projects
Capex Projects Product Project Status Remarks Commissioned • Currently, limited availability domestically and mostly imported Para Amino Phenol (PAP) Completed in Q4 FY’21 • Ramp up in the production ongoing to achieve the target by the end of FY’24 • Multi-purpose plant for forward integration with
Slide 9: Q2/H1-FY24 Highlights
Q2/H1-FY24 HIGHLIGHTS Valiant Organics Limited | Q2-2024 8
Slide 10: Consolidated Financial Highlights
CONSOLIDATED FINANCIAL HIGHLIGHTS Q2-FY24 CONSOLIDATED FINANCIAL HIGHLIGHTS H1-FY24 CONSOLIDATED FINANCIAL HIGHLIGHTS INR 2,031 Mn INR 4,049 Mn Operational Revenue Operational Revenue INR 155 Mn INR 394 Mn Operating EBITDA Operating EBITDA 7.63% 9.73% Operating EBITDA Margin Operating EBITDA Margin
Slide 11: Q2/H1-FY24 Operational Highlights
Q2/H1-FY24 Operational Highlights Q2-FY24 Revenue Break-up – Chemistries • The overall performance for the quarter was impacted mainly due to lower Others, 7% agrochemicals demand Chlorination, 19% • Dyes & pigments demand seem to be on a reversing trend on account of the Ammonolysis, increased sale
Slide 12: Key Chemistries: Revenues and Sales Volumes
Key Chemistries Chlorination (INR Mn) Hydrogenation (INR Mn) Ammonolysis (INR Mn) Others (INR Mn) 1, 200 1,106 740 549 155 800 180 600 1, 000 894 160 136 127 REVENUES 700 411 500 140 697 500 475 600 359 800 120 500 400 100 600 400 300 80 300 400 60 200 200 40 200 100 100 20 0 0 0 0 Q2-FY23 Q1-FY24 Q
Slide 13: Quarterly Consolidated Financial Performance
Quarterly Consolidated Financial Performance Particulars (INR Mn) Q2-FY24 Q2-FY23 Y-o-Y Q1-FY24 Q-o-Q Revenue from Operations 2,031 2,641 (23.1)% 2,018 0.6% Total Expenses 1,876 2,222 (15.6)% 1,779 5.5% EBITDA 155 419 (63.0)% 239 (35.1)% EBITDA Margins (%) 7.63% 15.87% (824) Bps 11.84% (421) Bps Oth
Slide 14: YTD Consolidated Financial Performance
YTD Consolidated Financial Performance Particulars (INR Mn) H1-FY24 H1-FY23 Y-o-Y Revenue from Operations 4,049 5,300 (23.6)% Total Expenses 3,655 4,563 (19.9)% EBITDA 394 737 (46.5)% EBITDA Margins (%) 9.73% 13.91% (418) Bps Other Income 68 38 78.9% Depreciation 176 139 26.6% Finance Cost 81 52 55.
Slide 15: Quarterly Standalone Financial Performance
Quarterly Standalone Financial Performance Particulars (INR Mn) Q2-FY24 Q2-FY23 Y-o-Y Q1-FY24 Q-o-Q Revenue from Operations 1,825 2,323 (21.4)% 1,766 3.3% Total Expenses 1,652 2,009 (17.8)% 1,563 5.7% EBITDA 173 314 (44.9)% 203 (14.8)% EBITDA Margins (%) 9.48% 13.52% (404)Bps 11.49% (201)Bps Other I
Slide 16: YTD Standalone Financial Performance
YTD Standalone Financial Performance Particulars (INR Mn) H1-FY24 H1-FY23 Y-o-Y Revenue from Operations 3,591 4,669 (23.1)% Total Expenses 3,216 4,094 (21.4)% EBITDA 375 575 (34.8)% EBITDA Margins (%) 10.44% 12.32% (188) Bps Other Income 5 16 (68.8)% Depreciation 166 132 25.8% Finance Cost 81 50 62.
Slide 17: Historical Financial Overview
HISTORICAL FINANCIAL OVERVIEW Valiant Organics Limited | Q2-2024 16
Slide 18: Historical Consolidated Income Statement
Historical Consolidated Income Statement Particulars (INR Mn) FY21 FY22 FY23 H1-FY24 Operational Income 7,548 11,533 10,518 4,049 Total Expenses 5,496 9,484 8,875 3,655 EBITDA 2,052 2,049 1,643 394 EBITDA Margins (%) 27.19% 17.77% 15.62% 9.73% Other Income 59 74 80 68 Depreciation 212 296 292 176 Fi
Slide 19: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars (INR Mn) FY22 FY23 H1-FY24 Particulars (INR Mn) FY22 FY23 H1-FY24 EQUITY 6,489 7,401 7,599 Non-Current Assets 6,652 7,682 8,132 a) Equity Share Capital 272 272 272 a) Property, Plant and Equipment 5,303 6,565 6,745 b) Other Equity 5,856 6,616 6,784 c) Right-Of-
Slide 20: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY21 FY22 FY23 H1-FY24 Revenue from Operations 5,742 9,484 9,116 3,591 Total Expenses 4,170 7,811 7,817 3,216 EBITDA 1,572 1,673 1,299 375 EBITDA Margins (%) 27.38% 17.64% 14.25% 10.44% Other Income 169 33 29 5 Depreciation 186 273 276 166
Slide 21: Standalone Balance Sheet
Standalone Balance Sheet Particulars (INR Mn) FY22 FY23 H1-FY24 Particulars (INR Mn) FY22 FY23 H1-FY24 EQUITY 6,031 6,661 6,804 Non-Current Assets 6,787 7,424 7,664 a) Equity Share Capital 272 272 272 a) Property, Plant and Equipment 5,085 6,092 6,255 b) Other Equity 5,755 6,385 6,528 b) Right-Of-Us
Slide 22: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 80.00% 1,309 1,279 2,052 1, 400 2,049 14, 000 11,533 2,100 70.00% 10,518 1,026 12, 000 1,800 1,643 1, 100 10, 000 60.00% 1,500 50.00% 8, 000 7,548 800 1,200 40.00% 27.19
Slide 23: Capital Market Information
Capital Market Information Share Price up to 30th September, 2023 30% 10% -10% -30% -50% -70% Oct-22 Nov-22 Dec-22 Jan-23 Feb-23 Mar-23 Apr-23 May-23 Jun-23 Jul-23 Aug-23 Sep-23 Valiant Organics Sensex Price Data (As on 30th September, 2023) INR Shareholding pattern (As on 30th September, 2023) Face
Slide 24: Disclaimer
Disclaimer Valiant Organics Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all event
Slide 25: Thank You
THANK YOU Valiant Organics Limited | Q2-2024 24